reported to cause muscle fibre necrosis,2 and magnesium was not given to our patient during his fast. Likewise vitamin E deficiency is described as a cause of obscure proximal myopathy3 and the serum concentration of this vitamin fell just below normal (14 ,umol/l; normal range 16 3-30 7 sLmol/l) by the end of the fast. The fact that a clinically evident myopathy did not appear until seven weeks after the fast was broken might suggest that its appearance was facilitated by the fluid retention which occurs in the early weeks of refeeding and might point to electrolyte shifts in the production of the syndrome.
Whatever its cause, clinical myopathy as the sequel to prolonged fasting appears to be a rare and self-limiting condition. Nevertheless, in view of its association with near-fatal cardiac arrhythmias in our patient it seems worth while to make regular measurements of voluntary muscle function during therapeutic starvation, to use evidence of muscle dysfunction as an indication to terminate the fast, and to monitor cardiac function in these patients with great care during the early weeks of refeeding.
We thank Dr G S Fell of the department of biochemistry, Glasgow Royal Infirmary, for measurements of vitamin E levels. 
Case report
A 41-year-old woman with a history of multiple cdrug abuse in her teens began taking Distalgesic in 1976 to relieve pain after a hysterectomy. She continued to take it regularly since it relieved the chronic back pain and headache from which she also suffered. After several months of uninterrupted consumption she had developed tolerance to its effects. During three years she had gradually increased her consumption to 32 tablets daily. While taking Distalgesic she felt well, confident, and better able to cope with life. When she attempted to stop taking it she had withdrawal symptoms consisting of severe headache, nausea, tremulousness, drowsiness, shivering, and watering eyes. She was also bad tempered, irritable, and subject to overwhelming misery and a severe craving for the drug. She made many importunate demands for prescriptions from her general practitioner. This culminated in her forging a prescription in June 1978, for which she received two years' probation.
Haematological testing gave normal results except for a raised cell volume (110 fl). y-Glutamyltransferase activity was also raised at 139 IU/1 and the calcium concentration slightly depressed (1-95 mmol/l (7-8 mg/100 ml)). A liver biopsy performed shortly after admission showed some cloudy swelling of the hepatocytes and an increased amount of "wear and tear" pigment. The patient denied alcohol abuse. Treatment consisted in withdrawing Distalgesic and giving methadone on a reducing scale, starting with 5 mg four times a day. Methadone was withdrawn completely within 10 days. While on it she had no withdrawal symptons. But on complete withdrawal of methadone she had low-grade symptoms of misery, nausea, headache, and slight tremulousness. When followed up as an outpatient she had not returned to taking Distalgesic and her symptoms were slowly abating.
Comment
Dextropropoxyphene is the psychoactive ingredient of several widely used analgesics ( over the preceding three years. A survey of patients discharged from hospitals in a health district showed that 1 in every 38 patients was receiving the drug (AC Bower, unpublished communication, 1979) . It is rapidly absorbed from the gastrointestinal tract and passes readily from the blood into body tissues. Dextropropoxyphene is structurally related to methadone and is similar in its onset and duration of action to codeine. It produces dependence of the morphine type. Initially it was thought to be a drug of low potential for abuse and relatively safe, and was introduced to compete with codeine as the analgesic of choice for chronic or recurrent mild-to-moderate pain. Dependence was first reported in 1963 in a 28-year-old-man who consumed 960 mg of dextropropoxyphene daily.3 Two further cases of dependence were reported in 1966 and another in 1969. Seemingly, prolonged administration of medications containing dextropropoxyphene leads to tolerance and dependence. Another danger is its ability to produce respiratory depression in relatively low doses. Controlled studies have failed to show that dextropropoxyphene is any more efficacious than paracetamol or aspirin alone.4 The use of drugs containing it should be reappraised in view of the hazards. So far no other case of vitamin BL2-deficient megaloblastic anaemia due to metformin therapy has been reported.
Case report
In 1960 a 47-year-old woman gradually developed polyuria and polydipsia.
Her height was 1-57 m and weight 88 kg. Her initial 21-hour postprandial venous blood glucose was 10-1 mmol/l (182 mg/100 ml). She was put on a 4-18 MJ (1000 kcal) diet containing 100 g carbohydrate. Chlorpropamide 250 mg daily was started after one year and within three years metformin 0 5 g twice daily was added because of persistent hyperglycaemia. She was not careful with her diet. When she was 54 her haemoglobin was 13-7 g/dl with normal indices. One year later serum vitamin B12 and serum folate concentrations were normal. When aged 58, after eight years of metformin therapy, she became clinically anaemic with lassitude and general debility. There were no neurological signs of posterior column disease or peripheral neuropathy. Her haemoglobin was 8-9 gfdl, her mean corpuscular volume (MCV) 106 fl (normal 84-99), and her mean cell haemoglobin (MCH) 36 pg (normal 30-35 pg). Serum concentrations were: bilirubin 164 ,umol/l (9-8 mg/100 ml) (normal 3-0-21-0 ,umol/l), lactate dehydrogenase 680 WL units (normal 220-440), alkaline phosphatase 4 0 KA units (normal), calcium 2-4 mmol/l (9-6 mg/100 ml), and phosphorus 1-2 mmol/l (3-7 mg/ 100 ml). Serum vitamin B13 was 60 ng/l (normal range 150-900) and serum folate 3-1 jg/l (normal range 3-5-24-0). Blood urea was normal.
A bone marrow aspirate showed a highly cellular pattern with all three cell lines present. The red and white cells were notably megaloblastic with predominance of the erythroid series. A modified combined Schilling test showed 6-2 % of a test dose of "8Co-labelled vitamin B12 excreted in 24 hours (normal range 10-1-32-1 %) and 4-8 % of a test dose of 57Co-labelled vitamin B1,2 gastric juice complex (normal range 10-1-30-1 %). There was evidence of gastric secretion of free hydrochloric acid (azuresin (Diagnex Blue) test). Concentration of serum gastrin was 65 ng/l (normal 9-150), serum iron 10 jsmol/l (55-9 jug/l00 ml) (normal 14-25 ttmol/l), total iron-binding capacity 65 umol/l (363 ,ug/100 ml) (normal 45-72 ,umol/l), and serum carotene 1 Hmol/l (53-7 ug/100 ml) (normal). Barium studies showed some flocculation and clumping in the proximal ileum but insufficient to suggest a major malabsorption syndrome. There were no local lesions and the terminal ileum was normal. The fat content of a three-day collection of faeces was normal. Intrinsic factor antibody was absent. Treatment was with cyanocobalamin 1000 ,Lg by injection daily at first and subsequently monthly. Serum vitamin B12 rose to over 1000 ng/l and haemoglobin to 13-9 g/dl, and MCV fell to 81 fl, and MCH to 28 pg. She died suddenly when aged 63, probably from myocardial infarction.
Comment
Side effects of metformin, apart from occasional initial nausea, are rare. Lactic acidosis is very unusual in correct clinical usage. 
